CG
BHVN

Cutler Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cutler Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,500
Closed -$1K – 5883
2022
Q2 		$1K Sell
8,500
-11,200
-57% -$1.43M ﹤0.01% 4864
2022
Q1 		$174K Buy
19,700
+10,400
+112% +$1.3M 0.01% 1294
2021
Q4 		$36K Buy
+9,300
New +$1.18M ﹤0.01% 2664
2021
Q1 		– Sell
-15,700
Closed -$36K – 6690
2020
Q4 		$36K Buy
15,700
+9,700
+162% +$822K ﹤0.01% 2247
2020
Q3 		$11K Buy
6,000
+4,500
+300% +$295K ﹤0.01% 2960
2020
Q2 		$7K Sell
1,500
-3,000
-67% -$160K ﹤0.01% 3153
2020
Q1 		$78K Sell
4,500
-1,300
-22% -$59.4K ﹤0.01% 1482
2019
Q4 		$27K Sell
5,800
-2,200
-28% -$109K ﹤0.01% 2046
2019
Q3 		$92K Sell
8,000
-10,100
-56% -$427K 0.01% 1117
2019
Q2 		$100K Buy
18,100
+13,100
+262% +$738K 0.01% 1093
2019
Q1 		$1K Buy
+5,000
New +$216K ﹤0.01% 3923
2018
Q3 		– Sell
-1,000
Closed -$1K – 5155
2018
Q2 		$1K Sell
1,000
-7,700
-89% -$244K ﹤0.01% 4100
2018
Q1 		$4K Buy
+8,700
New +$260K ﹤0.01% 3505

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Cutler Group's BHVN Position: Q4 2022 in Review

Cutler Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,300 shares — an estimated $196K sold.

Cutler Group first reported a position in BHVN in Q1 2018 and held it in 16 quarters. The position peaked at $1.32M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Cutler Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 1,300 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $196K.
  • Cutler Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 16 quarters.
  • Cutler Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.32M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.